Compare LGIH & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | AMPH |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 971.8M |
| IPO Year | 2013 | 2005 |
| Metric | LGIH | AMPH |
|---|---|---|
| Price | $48.22 | $18.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $75.90 | $28.38 |
| AVG Volume (30 Days) | 360.1K | ★ 710.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 0.14 |
| Revenue | ★ $1,705,504,000.00 | $719,887,000.00 |
| Revenue This Year | $2.32 | $6.90 |
| Revenue Next Year | $17.94 | $4.64 |
| P/E Ratio | $540.56 | ★ $137.93 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $16.65 |
| 52 Week High | $69.42 | $31.26 |
| Indicator | LGIH | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 44.87 |
| Support Level | $45.69 | $16.84 |
| Resistance Level | $49.51 | $20.08 |
| Average True Range (ATR) | 2.37 | 0.80 |
| MACD | 0.38 | 0.11 |
| Stochastic Oscillator | 76.19 | 73.53 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.